Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Encompass Health CorpEHC · Entity 3460 | Director · President & CEO | August 10, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Encompass Health Corp
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Encompass Health Common StockSEC Table I · non-derivative | Direct | 267,814 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Sale · Disposed 171,569 · Balance 269,393 F1: This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.93 to $125.92, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Row 2 · 2026-08-10 · Sale · Disposed 1,579 · Balance 267,814 F2: This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.93 to $126.22, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. |
Filing footnotes · ownership attribution and instrument terms
F1: This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.93 to $125.92, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F2: This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.93 to $126.22, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2017 Filed Aug 8, 2017 20:25 UTC | Encompass Health Corp HLS · Entity 3460 | Exercise / conversionHealthsouth Common Stock | 22,625 | $16.27 | $368,108.75 |
DisclosureSEC source: 0001127602-17-025233 · form4.xml · nonDerivative · entry 1 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 13:58 UTC | Encompass Health Corp HLS · Entity 3460 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 22,625 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001127602-17-024935 · form4.xml · derivative · entry 3 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,625 Underlying: Healthsouth Common Stock · 22,625 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 13:58 UTC | Encompass Health Corp HLS · Entity 3460 | SaleHealthsouth Common Stock | 22,625 | $42.55 | $962,693.75 |
DisclosureSEC source: 0001127602-17-024935 · form4.xml · nonDerivative · entry 2 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,509 F1 · price: This sale price per share is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.50 to $42.66, inclusive. The reporting person undertakes to provide to HealthSouth Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 13:58 UTC | Encompass Health Corp HLS · Entity 3460 | Exercise / conversionHealthsouth Common Stock | 22,625 | $16.27 | $368,108.75 |
DisclosureSEC source: 0001127602-17-024935 · form4.xml · nonDerivative · entry 1 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 23:04 UTC | Encompass Health Corp HLS · Entity 3460 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 46,754 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001127602-17-008701 · form4.xml · derivative · entry 1 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,754 Underlying: Healthsouth Common Stock · 46,754 shares Expires 2027-02-24 F1 · derivative.exercise_date: The option was exercisable in annual installments over a three-year period, at the rate of 33.3% per year commencing February 24, 2018. Read SEC document |
| February 21, 2017 Filed Feb 21, 2017 19:49 UTC | Encompass Health Corp HLS · Entity 3460 | Tax withholdingHealthsouth Common Stock | 1,401 | $42.00 | $58,842.00 |
DisclosureSEC source: 0001127602-17-007315 · form4.xml · nonDerivative · entry 3 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,509 F3 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:49 UTC | Encompass Health Corp HLS · Entity 3460 | GrantHealthsouth Common Stock | 15,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007315 · form4.xml · nonDerivative · entry 2 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,910 F2 · shares: This grant of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 19, 2015. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 19:49 UTC | Encompass Health Corp HLS · Entity 3460 | GrantHealthsouth Common Stock | 13,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007315 · form4.xml · nonDerivative · entry 1 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,708 F1 · shares: Award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 19:54 UTC | Encompass Health Corp HLS · Entity 3460 | Tax withholdingHealthsouth Common Stock | 812 | $41.48 | $33,681.76 |
DisclosureSEC source: 0001127602-17-006248 · form4.xml · nonDerivative · entry 1 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,150 F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:59 UTC | Encompass Health Corp HLS · Entity 3460 | Tax withholdingHealthsouth Common Stock | 4,928 | $41.24 | $203,230.72 |
DisclosureSEC source: 0001127602-17-000997 · form4.xml · nonDerivative · entry 1 Tarr Mark J · CIK 0001304057 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,962 F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 21:04 UTC | Encompass Health Corp HLS · Entity 3460 | PurchaseHealthsouth Common Stock | 6,371 | $39.29 | $250,316.59 |
DisclosureSEC source: 0001127602-16-066939 · form4.xml · nonDerivative · entry 1 Tarr Mark J · CIK 0001304057 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,890 F1 · kind: Because Mr. Tarr exercised expiring options by means of a broker assisted cashless exercise in August 2016, he has paid to the company in connection with this purchase the difference between the sale price of shares in the August exercise and the purchase price here. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.